The FDA accepts a New Drug Application for bezuclastinib to treat nonadvanced systemic mastocytosis based on positive data from the SUMMIT trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results